Complex CVR Will Enable Genzyme And Sanofi Shareholders To Share Potential Upside For Lemtrada

A six-part contingent value right included along with Sanofi-Aventis’ cash payment of $74 a share (about $20.1 billion) for Genzyme should enable both companies’ shareholders to share in the potential upside of Lemtrada (alemtuzumab) if it is approved as a treatment for multiple sclerosis.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet